Skip to main content
. Author manuscript; available in PMC: 2010 Jun 14.
Published in final edited form as: Psychopharmacology (Berl). 2009 Sep 17;207(3):381–390. doi: 10.1007/s00213-009-1666-5

Table 1.

Schematic representation of groups, number of subjects, and treatments from each experiment.

Group n Experiment 1 Experiment 2
Acquisition (Sessions 1–23) Drug Pretreatment (Sessions 24–30) nAChR (Sessions 31–35) NE-R (Sessions 41–52)
SAL 8 Active Lever: VS (FR1, FR2, FR5) SAL (IP/SC) 0, 0.05, 0.1 mg/kg mecamylamine 0, 0.1, 0.3, 1 mg/kg prazosin
0.4 NIC 8 0.4 NIC
3 BUP 9 3 BUP 0, 2.5, 5, 10 mg/kg propranolol
10 BUP 9 10 BUP
30 BUP 8 30 BUP